Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Human monoclonal thyroid stimulating autoantibody.

J Sanders1, M Evans, L D K E Premawardhana

  • 1FIRS Laboratories, RSR Ltd, Parc Ty Glas, Llanishen, CF14 5DU, Cardiff, UK.

Lancet (London, England)
|July 18, 2003
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Neo-adjuvant pembrolizumab in stage IV high-grade serous ovarian cancer: the phase II Neo-Pembro trial.

Nature communications·2025
Same author

Dermal wipe sampling method development and validation for semivolatile and nonvolatile flame-retardant compounds TBBPA and TPP for use in occupational exposure assessments.

Journal of occupational and environmental hygiene·2025
Same author

Revisiting hydrogen peroxide as radiosensitizer for solid tumor cells.

Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology·2024
Same author

The Barts Surgical Infection Risk (B-SIR) tool: external validation and comparison with existing tools to predict surgical site infection after cardiac surgery.

The Journal of hospital infection·2024
Same author

Search for Leptonic Decays of Dark Photons at NA62.

Physical review letters·2024
Same author

Tumor-infiltrating lymphocytes in HER2-positive breast cancer treated with neoadjuvant chemotherapy and dual HER2-blockade.

NPJ breast cancer·2024
Same journal

Convergence of metabolic risk in obesity and normal BMI: does risk disappear?

Lancet (London, England)·2026
Same journal

Metabolic traits in obesity and normal BMI in industrialised countries: a multi-country analysis of national population-based studies.

Lancet (London, England)·2026
Same journal

Safety and efficacy of mRNA vaccines: a mechanistic and public health perspective.

Lancet (London, England)·2026
Same journal

The US Ebola response and the future of global health leadership.

Lancet (London, England)·2026
Same journal

Daniel Mason: a tale of change.

Lancet (London, England)·2026
Same journal

The 2026 Wakley-Wu Lien Teh Prize Essay: why medicine, and why stay?

Lancet (London, England)·2026
See all related articles

Researchers produced a monoclonal autoantibody (MAb) that stimulates the thyroid by targeting the thyroid stimulating hormone (TSH) receptor (TSHR). This discovery aids in understanding Graves' disease pathogenesis.

Area of Science:

  • Endocrinology
  • Immunology
  • Molecular Biology

Background:

  • Graves' disease is an autoimmune disorder characterized by thyroid overstimulation.
  • Thyroid stimulating hormone receptor (TSHR) autoantibodies are key mediators in Graves' disease pathogenesis.
  • Characterizing these autoantibodies is crucial for understanding disease mechanisms.

Purpose of the Study:

  • To produce and characterize a monoclonal autoantibody (MAb) with thyroid stimulating activity from a Graves' disease patient.
  • To investigate the binding affinity and functional activity of the MAb to the TSHR.
  • To assess the MAb's potential as a tool for studying Graves' disease.

Main Methods:

  • Production of a monoclonal autoantibody (MAb) from patient lymphocytes.

Related Experiment Videos

  • Assessing MAb binding affinity to the TSH receptor (TSHR) using labeled TSH inhibition assays.
  • Measuring cyclic AMP production in cells transfected with TSHR to evaluate TSH-like activity.
  • Testing the inhibitory effect of serum TSHR autoantibodies on MAb binding.

    • Main Results:

    • A MAb with potent thyroid stimulating activity was successfully generated.
    • The MAb and its Fab fragment exhibited high-affinity binding to the TSHR.
    • The MAb inhibited labeled TSH binding and stimulated cyclic AMP production, mimicking TSH action.
    • Serum TSHR autoantibodies effectively inhibited the binding of the labeled MAb to the TSHR.

    Conclusions:

    • The generated human monoclonal autoantibody possesses characteristics consistent with endogenous TSHR autoantibodies found in Graves' disease.
    • This MAb serves as a valuable tool for further research into the pathogenesis of Graves' disease.
    • The availability of this MAb opens new avenues for studying TSHR-mediated autoimmune thyroid diseases.